Lab
Gentech Laboratories LLC
Gentech Laboratories LLC was paid $91.80M by Medicaid between Jul 2019 and Dec 2024, across 18 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 40% of everything it billed.
33Billing provider infoGENTECH LABORATORIES LLC
DALLAS, TX 75244
DALLAS, TX 75244
33aNPI1518406636assigned 02/22/2017
33bProvider typeClinical Medical Laboratory
28Total paid$91.80M
24GClaims1,132,422
24DCodes billed18
24AFirst – last monthJul 2019 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#6 of 436
Median peer was paid$17K
This provider vs. median5,322×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 720 | $0.00 | |
| 2020 | 683 | $15K | |
| 2021 | 7,796 | $144K | |
| 2022 | 220,511 | $10.06M | |
| 2023 | 585,432 | $44.46M | |
| 2024incomplete | 317,280 | $37.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 40% | 286,499 | 77,320 | $36.39M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 39% | 285,586 | 80,951 | $35.94M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 13% | 367,787 | 103,898 | $11.93M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 6.9% | 108,756 | 32,900 | $6.29M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 51,913 | 16,919 | $947K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29,854 | 12,927 | $265K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 888 | 870 | $32K |
| 86328 | <1% | 14 | 14 | $271.38 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 349 | 115 | $131.02 |
| 87481 | <1% | 117 | 115 | $32.75 | |
| 87500 | 0% | 30 | 30 | $0.00 | |
| 87640 | 0% | 49 | 49 | $0.00 |
6 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHAYER, VINCE (CEO)